114458-03-6

Basic information

• Product Name: 1,3-Dioxolane-4-acetic acid,2,2-dimethyl-5-oxo-
• Synonyms: 2,2-DiMethyl-5-oxo-1,3-dioxolane-4-acetic Acid;1,3-Dioxolane-4-acetic acid,2,2-dimethyl-5-oxo-
• CAS NO: 114458-03-6
• Molecular Formula: C₇H₁₀O₅
• Molecular Weight: 174.15
• Product Categories: Drug Intermediates
• Mol File: 114458-03-6.mol

Chemical Properties

• Boiling Point: 341.4±17.0 °C(Predicted)
• Appearance: /
• Density: 1.262±0.06 g/cm3(Predicted)
• PKA: 3.96±0.10(Predicted)
• CAS DataBase Reference: 1,3-Dioxolane-4-acetic acid,2,2-dimethyl-5-oxo-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-Dioxolane-4-acetic acid,2,2-dimethyl-5-oxo-(114458-03-6)
• EPA Substance Registry System: 1,3-Dioxolane-4-acetic acid,2,2-dimethyl-5-oxo-(114458-03-6)

Safety Data

• Hazardous Substances Data: 114458-03-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
1,3-Dioxolane-4-acetic acid, 2,2-dimethyl-5-oxois used as a reagent for the synthesis of degradation products of Phenylephrine (P320635 Hydrochloride salt) in over-the-counter products. Phenylephrine is a decongestant and vasoconstrictor used to relieve nasal congestion and other symptoms associated with allergies or the common cold. The compound plays a crucial role in the production of these products, ensuring their effectiveness and safety for consumer use.
Used in Chemical Research:
In addition to its applications in the pharmaceutical industry, 1,3-Dioxolane-4-acetic acid, 2,2-dimethyl-5-oxomay also be utilized in chemical research and development. Its unique structure and properties make it a valuable compound for exploring new reactions, synthesizing novel molecules, and understanding the underlying mechanisms of various chemical processes. This can lead to the discovery of new drugs, materials, and technologies with potential applications across various industries.

Upstream product

• 97-67-6 (S)-Malic acid 
• 67-64-1 acetone 
• 636-61-3 D-Malic acid 
• 77-76-9 2,2-dimethoxy-propane 
• 174563-88-3 (5R)-5-(2-hydroxyethyl)-2,2-dimethyl-1,3-dioxolan-4-one 
• 116-11-0 2-Methoxypropene 
• 617-48-1 malic acid 
• 1738-69-8 L-Leucine benzyl ester 

Downstream Products

• 265659-42-5 7-(1,2-O-isopropylidene-malyl) baccatin III 
• 242810-01-1 2-[2,2-dimethyl-5-oxo-1,3-dioxolan-4-yl]acetic acid benzyl ester 
• 161125-36-6 Fmoc-(R)-iSer-OH 
• 124724-88-5 (5S)-5-(2-hydroxyethyl)-2,2-dimethyl-1,3-dioxolan-4-one 
• 52079-23-9 (3S)-3-hydroxydihydrofuran-2(3H)-one 
• 1459706-57-0 C₂₈H₂₇N₃O₁₁ 
• 1459706-56-9 C₂₈H₂₈O₁₂ 
• 1459706-55-8 C₃₆H₄₀O₁₇ 
• 1459706-54-7 C₃₆H₄₀O₁₇ 
• 1459706-58-1 C₂₈H₂₉NO₁₁ 
• 1208866-61-8 C₂₁H₂₁N₃O₆ 

Relevant articles and documents

Structural and Functional Analysis of Bacterial Sulfonosphingolipids and Rosette-Inducing Factor 2 (RIF-2) by Mass Spectrometry-Guided Isolation and Total Synthesis

We have analyzed the abundance of bacterial sulfonosphingolipids, including rosette-inducing factors (RIFs), in seven bacterial prey strains by using high-resolution tandem mass spectrometry (HRMS2) and molecular networking (MN) within the Glob

Preparation method of alpha-hydroxyl-gamma-butyrolactone

The invention belongs to the field of preparation of organic compounds, and provides a preparation method of alpha-hydroxyl-gamma-butyrolactone. The method is characterized in that malic acid is used as a raw material, and alpha-hydroxyl-gamma-butyrolactone is synthesized with high yield through four steps of reactions, namely, carboxyl and alpha-hydroxyl protection, beta-carboxyl reduction, protecting group removal and internal esterification. The method has the advantages of easily available raw materials, mild reaction conditions and low cost, and is suitable for large-scale preparation of alpha-hydroxy-gamma-butyrolactone.

A Unified Approach to Phytosiderophore Natural Products

This work reports on the concise total synthesis of eight natural products of the mugineic acid and avenic acid families (phytosiderophores). An innovative ?east-to-west“ assembly of the trimeric products resulted in a high degree of divergence enabling the formation of the final products in just 10 or 11 steps each with a minimum of overall synthetic effort. Chiral pool starting materials (l-malic acid, threonines) were employed for the outer building blocks while the middle building blocks were accessed by diastereo- and enantioselective methods. A highlight of this work consists in the straightforward preparation of epimeric hydroxyazetidine amino acids, useful building blocks on their own, enabling the first synthesis of 3’’-hydroxymugineic acid and 3’’-hydroxy-2’-deoxymugineic acid.

Synthesis of Saxitoxin and Its Derivatives

The chiral synthesis of (+)-saxitoxin and its derivatives is described. Two consecutive carbon-nitrogen bonds at C-5 and C-6 in saxitoxin were effectively installed by the sequential Overman rearrangement of an allylic vicinal diol derived from d-malic acid. The bicyclic guanidine unit was constructed by the intramolecular aminal formation of an acyclic bis-guanidine derivative possessing a ketone carbonyl at C-4. From the bicyclic aminal intermediate, (+)-saxitoxin, (+)-decarbamoyl-β-saxitoxinol [(+)-dc-β-saxitoxinol], and the unnatural skeletal isomer, (-)-iso-dc-saxitoxinol, were synthesized.

L-malic acid dimer impurity and preparation method thereof

The invention provides an L-malic acid dimer impurity and a preparation method thereof. The L-malic acid dimer impurity (impurity X) is discovered and separated for the first time, and has a structureshown in the specification. The preparation method of the impurity X comprises the following steps: (1) protecting a carboxyl group at one side of L-malic acid to obtain a compound 1; (2) protectinga carboxyl group at the other side of the compound 1 to obtain a compound 2; (3) hydrolyzing the compound 2 under the condition of acetic acid/water/tetrahydrofuran to obtain a compound 3; (4) dehydrating and condensing the compound 3 to obtain a compound 4; and (5) hydrogenating the compound 4 to remove benzyl groups to obtain the impurity X. The impurity spectrum of malic acid stability researchis expanded, and the improvement of the malic acid quality standard is promoted. The compound property of the L-malic acid dimer impurity is studied, and the L-malic acid dimer impurity has positiveguiding significance for selection of storage conditions of malic acid.

PANTETHEINE DERIVATIVES AND USES THEREOF

The present disclosure relates to compounds of Formula (I), (II), or (II'): (I), (II), (II'), and pharmaceutically acceptable salts or solvates thereof. The present disclosure also relates to pharmaceutical compositions comprising the compounds and therapeutic and diagnostic uses of the compounds and pharmaceutical compositions.

Synthesis and structure reassignment of malylglutamate, a recently discovered earthworm metabolite

Malylglutamate, a newly identified metabolite in earthworms, was synthesized using a traditional peptide coupling approach for assembling the amide from protected malate and glutamate precursors. The proposed structure (1) and a diastereomer were synthesized, but their NMR spectra did not match the natural sample. Further analysis of the natural sample using HMBC spectroscopy suggested an alternative attachment of the malyl moiety, and β-malylglutamate (2) diastereomers were synthesized, L,L-2 and D,D-2. NMR spectra were an excellent match with the natural sample, and chiral-phase chromatography was employed to identify (a)-β-l-malyl-l-glutamate (2) as the isomer native to Eisenia fetida.

METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE

Abuse-resistant opioid compounds, drug delivery systems, pharmaceutical compositions comprising an opioid covalently bound to a chemical moiety are provided. Methods of delivering an active ingredient to a subject and methods of preventing opioid abuse are also provided.

STIMULUS-RESPONSIVE POLY(LACTIC-CO-GLYCOLIC)-BASED POLYMERS AND NANOPARTICLES FORMED THEREFROM

PLGA-based polymers include pendant nucleophiles protected with photocleavable protecting groups. Upon deprotection, the polymers degrade rapidly via intramolecular cyclization into small molecules. The polymer may be formulated as a nanoparticle, with an encapsulated payload, which may be an imaging agent, a bioactive agent or a pharmaceutical agent.